Biohaven Pharmaceutical Holding Company Ltd., also called Biohaven Pharmaceutical, is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. Read More The company was founded in September 2013 and is headquartered in New Haven, CT.